SCHEMBL4962298

SCHEMBL4962298

CCOC(=O)/C(C(=O)c1cccc2ccccc12)=C(\N)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 3/20 0.46
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 2/20 0.41
CDC25A P30304 1/20 0.41
CDC25C P30307 1/20 0.41
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
F7 P08709 1/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ELANE P08246 1/20 0.39
HPGD P15428 1/20 0.39
CNR2 P34972 1/20 0.39
NPC1 O15118 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4964192 0.89 CDC25B (0.46) CDC25BKDM4EALDH1A1CDC25ACDC25C
SCHEMBL3573848 0.84 LMNA (0.44) KDM4ELMNAALDH1A1KMT2AMEN1
SCHEMBL3563526 0.84 LMNA (0.44) KDM4ELMNAALDH1A1KMT2AMEN1
SCHEMBL697232 0.77 CDC25B (0.63) CDC25BKDM4ELMNAALDH1A1CDC25A
SCHEMBL3403487 0.76 MAPT (0.48) KDM4ELMNAALDH1A1KMT2AMEN1
SCHEMBL3403489 0.76 MAPT (0.48) KDM4ELMNAALDH1A1KMT2AMEN1
SCHEMBL4962300 0.74 DHODH (0.53) CDC25BKDM4ELMNAALDH1A1CDC25A
SCHEMBL3566705 0.74 CES2 (0.43) KDM4ELMNAALDH1A1KMT2AMEN1
SCHEMBL27798501 0.72 ALDH1A1 (0.59) CDC25BKDM4ELMNAALDH1A1CDC25A
SCHEMBL28745462 0.72 CDC25B (0.57) CDC25BKDM4EALDH1A1CDC25ACDC25C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof OXFORD FINANCE CORPORATION 2008-03-13 US claimed
EP-1742904-A4 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF UNIV CALIFORNIA (US) 2007-04-18 EP disclosed
EP-1742904-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-01-17 EP disclosed
WO-2005108347-A2 SUBSTITUTED ENAMINONES, THEIR DERIVATIVES AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof GABRB2, GABRB1, GABRB3 CDC25B 4622/4885KDM4E 2424/4885LMNA 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.